Oral Oncology
Volume 40, Issue 7 , Pages 742-750 , August 2004

Characterization of the human mandibular osteoblastic osteosarcoma cell line HOSM-2 after long-term culture

Received 6 January 2004 ,Accepted 12 January 2004.

References 

  1. Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75:203–210
  2. Clark JL, Unni KK, Dahlin DC, Devine KD. Osteosarcoma of the jaw. Cancer. 1983;51:2311–2316
  3. Bennett JH, Thomas G, Evans AW, Speight PM. Osteosarcoma of the jaws: A 30-year retrospective review. Oral Surg., Oral Med., Oral Pathol., Oral Radiol. Endodontics. 2000;90:323–333
  4. Dziedzic A, Emerich J, Grzesik W, Stachowicz W, Michalik J, Ostrowski K. Differences in the kinetics of the mineralization process in endochondral and intramembranous osteogenesis in human fetal development. J. Bone Min. Res. 1988;3:533–539
  5. Yoshikawa H, Ohishi M, Kohriki M, Yoshiura M, Osaki Y. Establishment and Characterisation of an osteoblastic clonal cell line from human mandibular osteosarcoma (HMOS-1). Oral Oncol. 1997;33:163–168
  6. Hamaguchi Y. Establishment of human osteosarcoma cell line from mandible and it's sensitivity of rhodamine 123 (Japanese). Mie Igaku. 1989;33:109–120
  7. Tagawa T, Nomura J, Kihira H, Murata M. A new established osteosarcoma cell line from human mandible. Mie Med. J. 1989;39:279–286
  8. Narita M, Murata T, Shimizu K, et al.  Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. Anticancer Drugs. 2003;14:377–381
  9. Gutierrez GE, Mundy GR, Katz MS. Alterations in hormone-sensitive adenylate cyclase of cloned rat osteosarcoma cells during long-term culture. J. Bone Min. Res. 1986;1:319–326
  10. Lotem M, Yehuda-Gafni O, Butnaryu E, Drize O, Peretz T, Abeliovic D. Cytogenic analysis of melanoma cell lines: subclone section in long-term melanoma cell culture. Cancer Genet. Cytogenet. 2003;142:87–91
  11. Rochet N, Dubousset J, Mateau C, et al.  Establishment, characterisation and partial cytokine expression profile of a new human osteosarcoma cell line (CAL 72). Int. J. Cancer. 1999;82:282–285
  12. Heremans H, Billiau A, Cassiman JJ, Mulier JC, Somer P. In vitro cultivation of human tumor tissues II. Morphological and virological characterization of three cell lines. Oncology. 1978;35:246–252
  13. Rodan SB, Imai Y, Thiede MA, et al.  Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 1987;47:4961–4966
  14. Bridge JA, Nelson M, McComb E, et al.  Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet. Cytogenet. 1997;95:74–87
  15. Fletcher JA, Gebhardt MC, Kozakewich HP. Cytogenetic aberrations in osteosarcomas. Cancer Genet. Cytogenet. 1994;77:81–88
  16. Hoogerwerf WA, Hawkins AL, Perlman EJ, Griffin CA. Chromosome analysis of nine osteosarcoma. Genes, Chromosomes Cancer. 1994;9:88–92
  17. Mertens F, Mandahl N, Orndal C, et al.  Cytogenetic finding in 33 osteosarcomas. Int. J. Cancer. 1993;55:44–50
  18. Soman NR, Wogan GN, Rhim JS. TPR-MET oncogenic rearrangement: detection by polymerase chain reaction amplification of the transcript and expression in human tumor cell line. Proc. Natl. Acad. Sci. USA. 1990;87:738–742
  19. Rubnitz JE, Pui C-H, Downing JR. The role of TEL fusion gene in pediatric leukemia. Leukemia. 1999;13:6–13
  20. Cazzaniga G, Tosi S, Aloisi A, et al.  The tyrosine kinase abl-rerated gene ARG is fused to ETV6 in an AML-M4Eo patient with a t(1;12)(q25;p13): molecular cloning of both reciprocal transcripts. Blood. 1999;12:4370–4373
  21. Sorenson GD. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 2000;6:2129–2137
  22. Hecht BK, Turc-Carel C, Chatel M, et al.  Cytogenetics of malignant gliomas. Cancer Genet. Cytogenet. 1995;84:9–14
  23. Abeliovich D, Yehuda O, Ben-Neriah S, Or R. Loss of Y chromosome. An age-related event or a cytogenetic marker of a malignant clone. Cancer Genet. Cytogenet. 1994;76:70–71
  24. United Kingdom Cancer Cytogenetics Group (UKCCG). Loss of the Y chromosome from normal and neoplastic bone marrows. Genes, Chromosomes Cancer 1992;5:83–88
  25. Radig K, Schneider-Stock R, Haeckel C, Neumann W, Roessner A. p53 Gene mutations in osteosarcomas of low-grade malignancy. Human Pathol. 1998;29:1310–1316
  26. Andreassen A, Oyjord T, Hovig E, et al.  p53 Abnormalities in different subtypes of human sarcomas. Cancer Res. 1993;53:468–471
  27. Toguchida J, Yamaguchi T, Ritchie B, et al.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 1992;52:6194–6199
  28. Li J, Hu S, Perng G, et al.  Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene. 1996;13:2379–2386
  29. Stein GS, Lian JB. Molecular mechanisms mediating proliferation/differentiation interrelationship during progressive development of the osteoblast phenotype. Endocrine Rev. 1993;14:424–442
  30. Siggelkow H, Niedhart C, Kurre W, et al.  In vitro differentiation potential of a new human osteosarcoma cell line (HOS 58). Differentiation. 1998;63:81–91

PII: S1368-8375(04)00029-6

doi: 10.1016/j.oraloncology.2004.01.015

Oral Oncology
Volume 40, Issue 7 , Pages 742-750 , August 2004

Article Tools

* Image Usage & Resolution